|
Germline alterations among Hispanic men with prostate cancer. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Invitae |
|
|
|
Stock and Other Ownership Interests - Invitae |
|
|
|
|
Stock and Other Ownership Interests - Genome Medical; Invitae; Maze Therapeutics; Pfizer Pharmaceutical |
|
Consulting or Advisory Role - Genome Medical; Maze Therapeutics; Pfizer |
Patents, Royalties, Other Intellectual Property - Royalties on a patented mouse model for Parkinson disease held by the National Institutes of Health and the University of California San Francisco |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - VieCure |
|
|
Consulting or Advisory Role - Boston Consulting Group |
Research Funding - eContour |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Dendreon; Exelixis; Janssen; Merck; Novartis; Pfizer; Sanofi; Tempus; Vividion Therapeutics |
Research Funding - Bayer (Inst); Pfizer (Inst); Tempus (Inst) |